Lindgren L, Kesselheim AS, Tu SS - Journal of Law, Medicine & Ethics
- Commentary & Opinion
- Innovation Incentives and Competition
- Regulation and Clinical Evidence
Summary:
Certification marks, similar to USDA Organic or Energy Star labels, have the potential to improve the perception and oversight of generic drug quality. Independent certification marks could be a cost-effective way to effectively communicate drug quality information to purchasers, incentivize manufacturers to exceed baseline quality standards, and improve consumer confidence in the generic drug supply.
VIEW SOURCE
Recent Work from PORTAL
How Congress Can Fix Expert Advisory Committees
Daval CJR, Kesselheim AS - STAT
- Commentary & Opinion
- Regulation and Clinical Evidence
International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway
Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy
- Research Publications
- Price, Value, and Access
- Regulation and Clinical Evidence
Politics and the Patient Encounter, in Dire Times
Avorn J - MedPage Today
- Commentary & Opinion
- Regulation and Clinical Evidence
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.